Topical Application Patents (Class 514/947)
  • Patent number: 9006272
    Abstract: Novel transdermal preparations combining a non-steroidal anti-inflammatory drug (NSAID) such as flunixin, are disclosed. Methods for using and administering such preparation in the treatment of inflammatory conditions in bovines, including bovine respiratory disease, are also disclosed.
    Type: Grant
    Filed: December 18, 2007
    Date of Patent: April 14, 2015
    Assignee: Intervet Inc.
    Inventors: Cheyney Meadows, Keith A. Freehauf, Robert D. Simmons, Allan J. Weingarten
  • Patent number: 8980309
    Abstract: This invention relates to novel transdermal or transmucosal pharmaceutical formulation having an active agent of testosterone which reduces the occurrences of contamination of other individuals and the transference to clothing of the user. The solvent system of the formulation includes a monoalkylether of diethylene glycol and a glycol present in specified ratios, and a mixture of water and alcohol. The invention also relates to a method for inhibiting or delaying crystallization of the active agent in a pharmaceutical formulation.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: March 17, 2015
    Assignee: Antares Pharma IPL AG
    Inventors: Dario Norberto R. Carrara, Arnaud Grenier
  • Patent number: 8846616
    Abstract: A method is presented for treating an inflammatory skin disorder in a human comprising: topically applying to the skin a composition comprising alpha-melanocyte stimulating hormone (?MSH) or an ?MSH analog in an amount effective to reduce skin inflammation in the human.
    Type: Grant
    Filed: November 9, 2010
    Date of Patent: September 30, 2014
    Assignees: Florida Agricultural and Mechanical University, The Board of Trustees at the University of Arkansas
    Inventors: Mandip Singh Sachdeva, Cheryl Armstrong, Melissa A. Brown
  • Patent number: 8841345
    Abstract: Compositions and methods for the treatment of premature ejaculation are provided wherein a composition comprising a topical anesthetic, a shear-thinning polymeric thickener, a lipophilic component that is selected from the group consisting of an aliphatic C1 to C8 alcohol, an aliphatic C8 to C30 ester, a liquid polyol and a mixture thereof, water and a buffer system that provides a buffered pH value for the composition in the range of about 3 to about 7.4 is administered to the penile meatus.
    Type: Grant
    Filed: March 22, 2004
    Date of Patent: September 23, 2014
    Assignee: Nexmed Holdings, Inc.
    Inventors: Mingqi Lu, Qin Wang, James L. Yeager, Y. Joseph Mo
  • Patent number: 8784878
    Abstract: A pharmaceutical composition for transdermal delivery comprising one or more physiologically active agents; one or more dermal penetration enhancers; and a volatile pharmaceutically acceptable carrier comprising a volatile solvent; and wherein the physiologically active agent and dermal penetration enhancer form an amorphous deposit upon evaporation of the volatile carrier, said amorphous deposit forming a reservoir within the stratum corneum; and (A) wherein the composition has a release rate profile of physiologically active agent so as to provide a ratio of the maximum concentration (Cmax) to the average concentration (Cavg) for the physiologically active agent over the dosage interval within the range of 1 to 10.
    Type: Grant
    Filed: December 11, 2012
    Date of Patent: July 22, 2014
    Assignee: Acrux DDS Pty Ltc.
    Inventors: Timothy Matthias Morgan, Nina Frances Wilkins, Kathryn Traci-Jane Klose, Barrie Charles Finnin, Barry Leonard Reed
  • Patent number: 8715736
    Abstract: Methods and formulations for treating a condition of the skin by delivering therapeutic formulations to the skin that translocates active substances across the stratum corneum barrier to a targeted skin tissue. The methods and formulations comprise active substances encapsulated within surface modified nanostructured lipid carrier nanoparticles.
    Type: Grant
    Filed: April 30, 2009
    Date of Patent: May 6, 2014
    Assignee: Florida Agricultural and Mechanical University
    Inventors: Mandip Singh Sachdeva, Ram Patlolla
  • Patent number: 8680154
    Abstract: Injectable veterinary composition comprising a fluorinated chloramphenicol or thiamphenicol derivative and a solvent system comprising an ether of 1,2-ethanediol oligo- or polymers, and a pyrrolidone solvent.
    Type: Grant
    Filed: December 20, 2005
    Date of Patent: March 25, 2014
    Assignee: Intervet International B.V.
    Inventor: Carole Barbot
  • Patent number: 8632813
    Abstract: Compositions and methods for the treatment of vasospasm are provided comprising applying an amount of a semi-solid vasoactive prostaglandin composition to the affected tissue. Also provided are methods of improving microcirculation in a replanted body part.
    Type: Grant
    Filed: October 19, 2007
    Date of Patent: January 21, 2014
    Assignee: Nexmed (Holdings), Inc.
    Inventors: Tian Wen, Liu Liu, Mingqi Lu, Jieshan Bai, Y. Joseph Mo
  • Patent number: 8618081
    Abstract: The present disclosure relates generally to compositions for cosmetic or pharmaceutical application. The compositions include a carrier and rheology modulators.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: December 31, 2013
    Assignee: Foamix Ltd.
    Inventors: Dov Tamarkin, Elana Gazal, Yohan Hazot, David Schuz, Irakliy Papiashvili
  • Patent number: 8586066
    Abstract: A topical, foamable composition is provided that includes at least one antifungal agent that is able to penetrate the upper layers of skin and is retained in or on an area to be treated for a prolonged period of time, and that has a residual non-volatile component content less than 25%. In addition, a method of treating fungal diseases including jock itch, tinea, dandruff and sebborheic dermatitis is provided, and includes applying to the affected area of patient requiring such treatment an antifungal composition.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: November 19, 2013
    Assignee: Delcor Asset Corporation
    Inventors: Greg Davey, Albert Zorko Abram
  • Patent number: 8529970
    Abstract: Materials with high levels of unsaponifiable matter, such as extracts from plants, produce hydrolysates with unique properties. Properties that are sought in traditional saponification of natural oils are a result of low levels of unsaponifiables. These properties include high levels of aqueous surfactant activity, water-solubility or ready water-dispersability, activity as foaming agents, and the like. An objective of traditional saponification processes is to increase the water-solubility and surfactant activity of naturally occurring materials. It has been found that the application of a hydrolysis process to materials, particularly materials with a high level of unsaponifiables (e.g., at least 6 weight percent of the material), produces a product with properties significantly different from those products resulting from the conventional saponification of materials with less than 6 weight percent of unsaponifiables.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: September 10, 2013
    Assignee: International Flora Technologies, Ltd.
    Inventors: James H. Brown, Lee Roy Copeland, Robert Kleiman, Melanie K. Cummings, Sambasivarao Koritala
  • Patent number: 8450311
    Abstract: Pharmaceutical compositions containing a fluoroquinolone antibiotic drug are disclosed. The compositions exhibit improved homogeneity, improved bioavailability, lower turbidity or a combination thereof. The composition can be use as otic or nasal compositions, but are particularly useful as ophthalmic compositions.
    Type: Grant
    Filed: May 29, 2009
    Date of Patent: May 28, 2013
    Assignee: Novartis AG
    Inventors: Inmaculada Campins, Nuria Jiménez, Roman Vidal, Nuria Carreras, Carmen Martinez, Francisco Javier Galán
  • Patent number: 8367116
    Abstract: The invention provides compositions and methods for treating a subject who has suffered from a central nervous system disorder. More particularly, the invention provides sustained polymeric drug delivery systems having a polymer particle, a therapeutic agent, and a buoyancy agent for direct delivery of therapeutic agents into the central nervous system.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: February 5, 2013
    Assignee: Seacoast Neuroscience, Inc.
    Inventors: Daniel Pratt, Samuel S. Macausland, Keith Baker
  • Patent number: 8357393
    Abstract: A pharmaceutical composition for transdermal delivery comprising one or more physiologically active agents; one or more dermal penetration enhancers; and a volatile pharmaceutically acceptable carrier comprising a volatile solvent; and wherein the physiologically active agent and dermal penetration enhancer form an amorphous deposit upon evaporation of the volatile carrier, said amorphous deposit forming a reservoir within the stratum corneum; and (A) wherein the composition has a release rate profile of physiologically active agent so as to provide a ratio of the maximum concentration (Cmax) to the average concentration (Cavg) for the physiologically active agent over the dosage interval within the range of 1 to 10.
    Type: Grant
    Filed: December 7, 2004
    Date of Patent: January 22, 2013
    Assignee: Acrux DDS Pty Ltd.
    Inventors: Timothy Matthias Morgan, Nina Frances Wilkins, Kathryn Taci-Jane Klose, Barrie Charles Finnin, Barry Leonard Reed
  • Patent number: 8333981
    Abstract: A fungus treatment composition used to deliver active drugs trans-nail as well as a method for producing the fungus treatment composition, which may contain up to 50% additive ingredients. Preferred embodiments of the invention may include fungus treatment compositions which provide high nail penetrating power, which have antifungal agents, which have antifungal essential oils, which have optimum drying and barrier properties, which have pharmaceutically elegant properties, or most preferably an embodiment having a total combination thereof.
    Type: Grant
    Filed: October 6, 2008
    Date of Patent: December 18, 2012
    Assignee: Humco Holding Group, Inc.
    Inventor: John Olin Trimble
  • Patent number: 8329760
    Abstract: A pharmaceutical compositions in the form of an emulsion and containing a continuous liquid phase, for example, an aqueous phase, liquid droplets dispersed in the continuous phase, a pharmaceutically active compound, a Hseih enhancer, and a hydrocolloid emulsifying agent and in which, for example, the active compound is dissolved in the aqueous phase or in the liquid droplets, and the use of such composition to treat a condition in a patient, for example, diabetes.
    Type: Grant
    Filed: July 17, 2009
    Date of Patent: December 11, 2012
    Assignee: CPEX Pharmaceuticals, Inc.
    Inventor: Robert J. Gyurik
  • Patent number: 8287846
    Abstract: The present invention relates to odour improved dermatological or cosmetic preparations comprising N-acetylcysteine and a polyol system containing one or more polyols as masking odour agents. The emulsions of the present invention are useful in the treatment of dermatological disorders or cosmetic skin conditions.
    Type: Grant
    Filed: July 13, 2007
    Date of Patent: October 16, 2012
    Assignee: ZAMBON S.p.A.
    Inventors: Luca Rampoldi, Alberto Moretto, Alessandro Grassano
  • Patent number: 8252308
    Abstract: The present invention provides a substantially clear gel designed to reduce itching discomfort when applied to the vulvar tissue. The gel includes at least one anesthetic, protectant, emulsifier, and pH modifier, such as a base. The gel has a pH adapted to vulvar use and may be applied to the vulvar tissues.
    Type: Grant
    Filed: January 27, 2005
    Date of Patent: August 28, 2012
    Assignee: C.B. Fleet Company Inc.
    Inventors: Nelson Ayala, Michael L. Caswell
  • Patent number: 8217062
    Abstract: A topical composition comprising a dihydropyridine calcium antagonist, a stiffening agent and a release modifier. The stiffening agent comprises a fatty alcohol, a fatty acid sorbitane ester, or a fatty acid glycerol ester, having a hydrocarbon chain containing 12 to 22 carbon atoms and having a melting point of about 45 to 750° C. The release modifier comprises a fatty alcohol, a fatty alcohol glycol ether, a fatty acid alkyl ester, a fatty acid glycerol ester, or a fatty acid sorbitane ester, having a hydrocarbon chain containing 12 to 18 carbon atoms and having a melting point of about ?10 to 400° C. Use of such a composition for the treatment and/or prophylaxis of a dermal or mucosal disorder, preferably an anorectal disorder associated with high anal pressure or anal sphincter spasm.
    Type: Grant
    Filed: August 31, 2007
    Date of Patent: July 10, 2012
    Assignee: Moberg Derma AB
    Inventors: Johan Engblom, Birgitta Svensson, Anette Abrahamsson, Åke Lindahl
  • Patent number: 8153142
    Abstract: A skin treatment composition of the present invention is an external composition for skin comprising an alkylene oxide derivative expressed by Formula (I): R1O-[(AO)m(EO)n]—R2??(I) wherein AO is an oxyalkylene group of C3 or C4; EO is an oxyethylene group; m and n are 1?m?70 and 1?n?70 respectively, wherein EO is 20˜80% by weight with respect to a total of AO and EO; each of R1 and R2 is a hydrogen or a hydrocarbon group having C1-4. The alkylene oxide derivative (I) has a moisturizing effect, a rough skin improving effect, a stickiness improving effect, and a transdermal absorption promoting effect. When a refreshing agent is used together therewith in the composition of the present invention, the refreshing effect lasts for a long time and it is excellent in feeling of use without skin stimulation.
    Type: Grant
    Filed: August 11, 2009
    Date of Patent: April 10, 2012
    Assignees: Shiseido Co., Ltd., NOF Corporation
    Inventors: Takashi Ohmori, Tohru Okamoto, Hiroyuki Kakoki, Reji Miyahara, Tomiyuki Nanba, Toshihiko Nakane, Yohei Hamano, Eriko Takeoka
  • Patent number: 8052984
    Abstract: The invention is an increased effectiveness of allylamine drug compounds for topical treatment of fungal infections of skin and skin appendages. The allylamine active ingredient is prepared in an acidic environment; the acidic environment altering the physiochemical properties of the active ingredient resulting in the active ingredient having a positive charge. The positive charge and enhancers used in the formula allow for increased penetration of the active ingredient through skin and skin appendages. The positively charged active ingredients are either dissolved in the vehicle directly or dissolved in a plurality of beads suspended in the vehicle.
    Type: Grant
    Filed: February 5, 2008
    Date of Patent: November 8, 2011
    Assignee: Biophile Corporation, Ltd.
    Inventors: Pichit Suvanprakorn, Panida Vayumhasuwan, Nardo Zaias
  • Patent number: 8034845
    Abstract: Novel formulations containing a fluorinated chloramphenicol or thiamphenicol derivative antibiotic such as florfenicol, and methods for using such formulations in the treatment and prevention of infectious diseases of bovines and swine, including bovine respiratory disease.
    Type: Grant
    Filed: May 28, 2004
    Date of Patent: October 11, 2011
    Assignee: Intervet Inc.
    Inventors: Keith A. Freehauf, Allan Weingarten, Robert D. Simmons, Kanwal Jit Varma
  • Patent number: 8026238
    Abstract: A topical, foamable composition is provided that includes at least one antifungal agent that is able to penetrate the upper layers of skin and is retained in or on an area to be treated for a prolonged period of time, and that has a residual non-volatile component content of less than 25%. In addition, a method of treating fungal diseases including jock itch, tinea, dandruff and sebborheic dermatitis is provided, and includes applying to the affected area of a patient requiring such treatment an antifungal composition.
    Type: Grant
    Filed: December 2, 2008
    Date of Patent: September 27, 2011
    Assignee: Stiefel Research Australia, Pty Ltd
    Inventors: Greg Davey, Albert Zorko Abram
  • Patent number: 7923032
    Abstract: The invention provides compositions and methods for treating a subject who has suffered from a central nervous system disorder. More particularly, the invention provides sustained polymeric drug delivery systems having a polymer particle, a therapeutic agent, and a buoyancy agent for direct delivery of therapeutic agents into the central nervous system.
    Type: Grant
    Filed: November 26, 2003
    Date of Patent: April 12, 2011
    Assignee: Seacoast Neuroscience, Inc.
    Inventors: Daniel Pratt, Samuel S. MacAusland, Keith Baker
  • Patent number: 7858607
    Abstract: The invention concerns a concentrated hormone pharmaceutical composition having from about 0.6 to about 80% of at least one hormone; from about 20 to about 90.4% of at least one solvent, and optionally a pharmaceutically acceptable carrier. The concentrated hormone pharmaceutical composition according to this invention provides a concentrated pharmaceutical composition that is easy to use and saves time and money to the pharmacies dealing with BHRT pharmaceutical products.
    Type: Grant
    Filed: September 22, 2003
    Date of Patent: December 28, 2010
    Inventor: Stephen A. Mamchur
  • Patent number: 7858114
    Abstract: Disclosed is a percutaneous absorption preparation which enables the stable administration of an antidementia drug over a long period of time. More particularly, the percutaneous absorption preparation of the antidementia drug which is used as a plaster on skin comprises at least an adherent layer, an intermediate membrane, and a drug reservoir layer sequentially from the side which is plastered on skin, wherein the drug reservoir layer comprises at least an antidementia drug, an aminated polymer, a polyhydric alcohol, and one or more carboxylic acid esters, the intermediate membrane enables the controlled permeation of the antidementia drug into the side of skin, the adherent layer enables the plastering of the percutaneous absorption preparation on skin, and is permeable to the antidementia drug.
    Type: Grant
    Filed: May 7, 2007
    Date of Patent: December 28, 2010
    Assignee: Teikoku Seiyaku Co., Ltd.
    Inventor: Takeshi Ito
  • Patent number: 7858662
    Abstract: The invention relates to a medicament containing a compound of general formula (1), where R1=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C11-C21 alkyl, alkylene or alkynyl group, preferably a C11-C15 alkyl, alkylene or alkynyl group, particularly a C11-C13 alkyl, alkylene or alkynyl group, most preferably a C13 alkyl group, R2=independently, a straight or branched C1-C8 alkyl, alkylene or alkynyl group, preferably a C1-C6 alkyl, alkylene or alkynyl group, in particular a C2-C4 alkyl, alkylene or alkynyl group, most preferably a C3 alkyl group, a —[CH2—(CH2)m—O]nH group with n=1 to 10, preferably n=1 to 5, m=1 to 5, preferably m=1 to 3, a —CH2—[CH—(OH)]p[CH2—(R3)]— group, where R3=independent H or OH, p=1 to 7, preferably p=1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/or tu
    Type: Grant
    Filed: November 18, 2002
    Date of Patent: December 28, 2010
    Assignee: MediGene AG
    Inventors: Yunik Chang, Robert Lathrop, Erwin Böhm, Irene Gander-Meisterernst, Regina Greger, Johanna Holldack, Ulrich Moebius
  • Patent number: 7666914
    Abstract: Disclosed herein is a preparation for topically delivering and localizing therapeutic agents, comprising: a vasoconstrictor for retarding vascular dispersion of a therapeutic agent; and a penetration enhancer for facilitating penetration of the vasoconstrictor and the therapeutic agent through a patient's skin. Further disclosed is an associated method of topically delivering and localizing therapeutic agents, comprising the steps of: using a vasoconstrictor for retarding vascular dispersion of a therapeutic agent; in combination with using a penetration enhancer for facilitating penetration of the vasoconstrictor and the therapeutic agent through a patient's skin. Also disclosed are various courses of treatment which comprise applying the various disclosed combinations of agents to the patient's skin.
    Type: Grant
    Filed: June 3, 2004
    Date of Patent: February 23, 2010
    Inventors: David M. Richlin, George R. Doherty
  • Patent number: 7582677
    Abstract: A topical formulation which includes a lignan or lignan ester in a dermatologically acceptable vehicle. The formulation can be either a cosmetic formulation or a pharmaceutical formulation.
    Type: Grant
    Filed: May 15, 2003
    Date of Patent: September 1, 2009
    Assignee: Hormos Medical Corp.
    Inventors: Helena Korte, Veli-Matti Lehtola, Mikko Unkila, Mervi Hiilovaara-Teijo, Markku Ahotupa
  • Patent number: 7553835
    Abstract: The subject matter relates to a topical, foamable composition including at least one antifungal agent, said composition characterised in that said at least one antifungal agent is able to penetrate the upper layers of skin and is retained in or on an area to be treated for a prolonged period of time, and in that it has a residual non-volatile component content of less than 25%. The subject matter furthermore relates to a method of treating fungal diseases including jock itch, tinea, dandruff and sebborheic dermatitis by applying to the affected area of a patient requiring such treatment the antifungal composition.
    Type: Grant
    Filed: October 19, 1998
    Date of Patent: June 30, 2009
    Assignee: Stiefel Research Australia Pty Ltd
    Inventors: Greg Davey, Albert Zorko Abram
  • Patent number: 7467987
    Abstract: A treatment brassiere includes a breasts-supporting garment and a treatment layer. The breast-supporting garment includes at least a breast support having an inner surface and a securing device for securing the breast support on a user that the inner surface of the breast support is contacting with the breast surface of the user. The treatment layer, which is made of a non-absorptive material with respect to a breast treatment, is fittingly provided on the inner surface of the breast support, wherein the treatment layer form as a treatment barrier between the breast surface of the user and the inner surface of the breasts-supporting garment for substantially keeping the breast treatment on the breast surface.
    Type: Grant
    Filed: April 20, 2004
    Date of Patent: December 23, 2008
    Inventor: Naila K. Khalaf
  • Patent number: 7438926
    Abstract: This invention relates to a method for inhibiting a decrease in the transdermal flux of an agent that is being transdermally delivered or sampled over a prolonged period of time wherein the delivery or sampling involves disrupting at least the stratum corneum layer of the skin to form pathways through which the agent passes. The desired result is achieved by co-delivering or co-sampling the agent with an amount of at least one anti-healing agent wherein the amount of the anti-healing agent is effective in inhibiting a decrease in the agent transdermal flux compared to when the delivery or sampling of the agent is done under substantially identical conditions except in the absence of the anti-healing agent(s).
    Type: Grant
    Filed: September 8, 2001
    Date of Patent: October 21, 2008
    Assignee: Alza Corporation
    Inventors: Michel Cormier, Juanita Johnson, Wei Qi Lin, James Matriano, Peter Daddona
  • Patent number: 7422756
    Abstract: The invention concerns a skin preparation for moistening human skin comprising a combination of a component A and a component B, wherein A includes at least two saturated C9-C31 fatty acids selected from the group consisting of iso- and anteiso fatty acids, whereby component B consists of cholesterol in an amount of 5-15% by weight of component A.
    Type: Grant
    Filed: June 12, 2002
    Date of Patent: September 9, 2008
    Assignee: Knut Haadem AB
    Inventor: Knut Haadem
  • Patent number: 7374770
    Abstract: Polyethylene glycol ethers of alkyl alcohols having the general formula CH3(CH2)xCH2(OCH2CH2)nOH wherein x is 8 to 20 (of which ceteareth-20, steareth-20 and steareth-100 are preferred), poloxamer 185, poloxamer 407, N,N-dimethyl dodecylamine N-oxide, and mixtures thereof, are employed to increase follicular delivery and/or follicular residence time of certain water soluble ornithine decarboxylase inhibitors of which 2(difluoromethyl)-2,5-diamino pentanoic acid and its pharmaceutically acceptable salts, hydrates, optical enantiomers and racemic mixture are preferred.
    Type: Grant
    Filed: August 13, 2002
    Date of Patent: May 20, 2008
    Assignee: SkinMedica, Inc.
    Inventors: Joyce T. Chou, Prakash Parab
  • Patent number: 7326420
    Abstract: A benzoyl peroxide composition having increased potency includes benzoyl peroxide, a tertiary amine and/or a transition metal, and a base that increases radicals formed by the peroxide.
    Type: Grant
    Filed: August 12, 2004
    Date of Patent: February 5, 2008
    Inventors: Craig G. Burkhart, Craig N. Burkhart
  • Patent number: 7323185
    Abstract: This invention relates to methods of increasing the efficacy of peroxides such as benzoyl peroxide in the treatment of skin conditions such as acne. In a preferred embodiment, the invention relates to methods of increasing radicals formed by peroxides on/in the skin, more specifically near/in the comedone, for topical use in dermatology. In a specific embodiment, the invention relates to the use of transitional metals such as Cu(1) and ferrous ions to increase the efficacy of peroxides such as benzoyl peroxide. In another embodiment, the invention relates to a method by which a peroxide such as benzoyl peroxide and its activator are added to the skin surface at the same time. In another embodiment, the invention relates to the use of a more soluble form of peroxide such as benzoyl peroxide to increase its efficacy. In another embodiment, the invention relates to the addition of a side chain to a peroxide such as benzoyl peroxide so that it is activated by light.
    Type: Grant
    Filed: May 18, 2004
    Date of Patent: January 29, 2008
    Inventor: Craig N. Burkhart
  • Patent number: 7270834
    Abstract: A pharmaceutical composition to be externally applied as a topical preparation for treating several diseases, the composition comprising dimethylsulfoxide (DMSO) and ozone. A method for obtaining the composition by ozonizing DMSO and a method for treating diseases by applying the composition are also provided.
    Type: Grant
    Filed: June 3, 2002
    Date of Patent: September 18, 2007
    Inventors: Haydee Alba Stenti, Claudia Pirillo, Jose Maria Pastoriza
  • Patent number: 7267827
    Abstract: An analgesic/anti-inflammatory pharmaceutical dosage form which comprises an effective amount of an active ingredient selected from the group consisting of racemic 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, optically active forms thereof and pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable excipient or diluent, said dosage form being an intranasally administrable dosage form.
    Type: Grant
    Filed: July 13, 2001
    Date of Patent: September 11, 2007
    Assignee: Recordati S.A.
    Inventors: Giancarlo Santus, Giuseppe Bottoni, Ettore Bilato
  • Patent number: 7244447
    Abstract: A method is provided for increasing the permeability of skin or mucosal tissue to transdermally administered nonsteroidal anti-inflammatory drugs (NSAIDs). The method involves use of a specified amount of a hydroxide-releasing agent, the amount optimized to increase the flux of the NSAID through a body surface while minimizing the likelihood of skin damage, irritation or sensitization. Formulations and drug delivery systems for co-administering a hydroxide-releasing agent with an NSAID are provided as well.
    Type: Grant
    Filed: July 30, 2003
    Date of Patent: July 17, 2007
    Assignee: Dermatrends, Inc.
    Inventors: Tsung-Min Hsu, Eric C. Luo
  • Patent number: 7241460
    Abstract: The invention provides a method of treatment of a human or non-human subject to combat sub-dermal soft tissue pain therein, said method comprising administering to a subject in need thereof an effective amount of a physiologically tolerable strontium compound.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: July 10, 2007
    Assignee: Santosolve AS
    Inventors: Egil Jellum, Bjørn Jarl Fagerlund, Clas Magne Kjølberg, Jo Klaveness
  • Patent number: 7235257
    Abstract: This invention relates to external drugs for dermal application which have a migraine-alleviating effect, in more detail ointments and patches comprising in mixing l-menthol and an essential oil into a base containing a hydrophilic high-molecular weight compound, a polyhydric alcohol and water.
    Type: Grant
    Filed: December 14, 1999
    Date of Patent: June 26, 2007
    Assignees: Rohto Pharmaceutical Co., Ltd., Teikoku Seiyaku Co., Ltd.
    Inventors: Hideakira Yokoyama, Hidetoshi Hamamoto
  • Patent number: 7186706
    Abstract: The present invention provides compositions, methods, and kits for improving health in a woman having elevated SHBG levels, or who is receiving oral estrogen supplementation, by non-orally administering an effective amount of an androgenic steroid. Further, the present invention provides compositions, methods, and kits for coadministering an effective amount of an orally administered estrogen and an effective amount of a non-orally administered androgenic steroid for women in need of estrogen supplementation.
    Type: Grant
    Filed: October 22, 2002
    Date of Patent: March 6, 2007
    Assignee: Watson Pharmaceuticals, Inc.
    Inventors: Theresa Rosario-Jansen, Norman A. Mazer
  • Patent number: 7105571
    Abstract: The invention provides methods and compositions for treating erectile dysfunction. The methods include the step of placing within the fossa navicularis of the patient an effective erection-inducing amount of a vasoactive prostaglandin composition of a semi-solid consistency. The composition comprises a vasoactive prostaglandin, a penetration enhancer, a shear-thinning polysaccharide, a lipophilic compound, and an acidic buffer system. The penetration enhancer is an alkyl-2-(N-substituted amino)-alkanoate ester, a (N-substituted amino)-alkanol alkanoate, or a mixture of these enhancers. The lipophilic compound may be an aliphatic C1 to C8 alcohol, aliphatic C2 to C30 ester, an aliphatic C8 to C30 ester, or a mixture of these. The composition includes a buffer system providing a buffered pH value for said composition in the range of about 3 to about 7.4.
    Type: Grant
    Filed: September 6, 2002
    Date of Patent: September 12, 2006
    Assignee: NexMed Holdings, Inc.
    Inventors: James L. Yeager, Nadir Büyüktimkin, Servet Büyüktimkin
  • Patent number: 7094407
    Abstract: The present invention relates to a fusion peptide, in which a self cell-penetrating Tat peptide having a self penetrating signal is bound to a human Type-I collagen C-terminal derived peptide, a preparation thereof, and a skin anti-aging cosmetic composition comprising the same. Since the fusion peptide, in which the Tat peptide is bound to the human Type-collagen C-terminal derived peptide is highly stable and has a superior skin absorption capability, the present invention provides a skin anti-aging agent having superior synthesis of collagen and hyaluronic acid, anti-aging effects, and improved durability of the effects.
    Type: Grant
    Filed: September 16, 2002
    Date of Patent: August 22, 2006
    Assignee: LG Household & Health Care Ltd.
    Inventors: Nae-Gyu Kang, Young-Sook Song, Sun-Gyoo Park, Yong-Hwa Lee, Wan-Goo Cho, Seh-Hoon Kang
  • Patent number: 7081253
    Abstract: A description is given of the use of a nanodispersion, which comprises (a) a membrane-forming molecule, (b) a coemulsifier and (c) a lipophilic component, in pharmaceutical end formulations, the nanodispersion being obtainable by (?) mixing the components (a), (b) and (c) until a homogeneous clear liquid is obtained, and (?) adding the liquid obtained in step (?) to the water phase of the pharmaceutical end formulations, steps (?) and (?) being carried out without any additional supply of energy. The nanodispersions used according to this invention are suitable as transport vehicles for pharmaceutical active agents.
    Type: Grant
    Filed: May 6, 1999
    Date of Patent: July 25, 2006
    Assignees: Ciba Specialty Chemicals Corporation, Vesifact AG
    Inventors: Andreas Werner Supersaxo, Hans Georg Weder, Dietmar Hüglin, Joachim Friedrich Röding
  • Patent number: 7029659
    Abstract: A topical mousse composition including an occlusive agent; an aqueous solvent; and an organic cosolvent, wherein the occlusive agent is present in an amount sufficient to form an occlusive layer on the skin.
    Type: Grant
    Filed: January 27, 2004
    Date of Patent: April 18, 2006
    Assignee: Connetics Australia Pty Ltd.
    Inventor: Albert Zorko Abram
  • Patent number: 7029663
    Abstract: A substantially anhydrous stable ointment containing Aspirin which is characterized in using gelation hydrocarbon and/or vaseline as a base. The ointment is superior in stability and can be stored for a long term.
    Type: Grant
    Filed: June 23, 1998
    Date of Patent: April 18, 2006
    Assignee: Teikoku Seiyaku Co., Ltd.
    Inventors: Noriko Mizobuchi, Yuichi Hasegawa, Mitsuhiro Kawada, Shin-ichi Hisaichi
  • Patent number: 7025972
    Abstract: An allergen and blocking sorbent for topical application to the skin comprising a surface-modified layered material, such as an intercalated clay, dispersed in a cosmetically acceptable solvent. The organic surface modifier is an organic molecule that contains a substantial dipole moment sufficient to bond, through ion-dipole interactions, with an exchangeable cation on the inner surface of adjacent clay platelets. Suitable organic surface modifiers include aldehydes, ketones, carboxylic acids, alcohols, phenols, ethers, catecols, lactams, lactones and pyrrolidones. The preferred layered material useful in this invention includes the entire family of smectite type clays. The composition is topically applied to the skin to absorb or adsorb (hereinafter “sorb” or “sorbent”) via intercalation between spaced layers of the layered material, and block allergenic organic compounds from plants such as poison ivy, poison oak, and poison sumac, thus preventing skin rashes.
    Type: Grant
    Filed: May 30, 2001
    Date of Patent: April 11, 2006
    Inventor: Gary W. Beall
  • Patent number: 6989152
    Abstract: A compound for reducing the incidence of pseudofolliculitis combines a mild skin astringent, an oil based epidermal softener, and a hair stiffener. One embodiment of the compound combines refined powdered oatmeal and emollient of the compound combines refined powdered oatmeal and emollient oil, such as mink oil and liquid vitamin A in a petroleum jelly base. The mixture is applied by being massaged into the skin prior to lathering and then again immediately after the rinsing of the face after shaving. Continual usage significantly reduces the eruption of pseudofolliculitis. The compound would also include Borage Oil and Evening Primrose Oil rich in Gamma Linolenic Acid (GLA).
    Type: Grant
    Filed: September 10, 2003
    Date of Patent: January 24, 2006
    Inventors: John Campbell, Charles Fox
  • Patent number: 6979454
    Abstract: A biologically active stick composition comprising a biologically active agent dissolved in a carrier system including an unsaturated fatty acid alcohol in mutual dissolution with an alkylene glycol as a solvent for said biologically active agent and a stiffening agent therefor, said stiffening agent imparting stick consistency to the composition, said alkylene glycol preferably being present in an amount of more than 12%. The composition can be prepared by dissolving the active agent in the solvent, combining the solution with the stiffening agent and shaping the formulation into a stick. The composition is especially intended for use as a medicament, preferably in the treatment of dermatological conditions, where it has been found to possess outstanding bioavailability properties.
    Type: Grant
    Filed: April 29, 1997
    Date of Patent: December 27, 2005
    Assignee: Jagotec AG
    Inventors: Åke Lindahl, Rickard Bryland